New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: “Both the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
News For RHHBY From The Last 14 Days
Check below for free stories on RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:08 EDTRHHBYUltragenyx appoints Sunil Agarwal, M.D. as Chief Medical Officer
Subscribe for More Information
July 22, 2014
05:21 EDTRHHBYRoche announces Genentech Avastin granted priority review by FDA
Subscribe for More Information
July 21, 2014
07:11 EDTRHHBYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
06:43 EDTRHHBYGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:42 EDTRHHBYRoche not looking for big acquisitions, Reuters says
Subscribe for More Information
July 17, 2014
17:42 EDTRHHBYCepheid says Roche patent suit will not have material adverse impact on results
Subscribe for More Information
July 16, 2014
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
05:37 EDTRHHBYGenentech Avastin granted priority review by FDA
Subscribe for More Information
July 14, 2014
11:20 EDTRHHBYExelixis seen as potential target for Roche, TheStreet says
Subscribe for More Information
July 10, 2014
10:02 EDTRHHBYRoche unit, Merck KGaA to develop companion test for cancer treatment
Ventana Medical Systems, a member of the Roche Group (RHHBY), announced it has entered into an agreement with Merck KGaA (MKGAY), which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic for an undisclosed target using Ventana's proprietary diagnostic assays.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use